Colofiore JR - Search Results

1

Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation.

Martin DS, Stolfi RL, Colofiore JR, Nord LD. Martin DS, et al. Among authors: colofiore jr. Anticancer Drugs. 1996 Aug;7(6):655-9. doi: 10.1097/00001813-199608000-00006. Anticancer Drugs. 1996. PMID: 8913434

2

A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.

Kelsen D, Martin DS, Colofiore J, Sawyer R, Coit D. Kelsen D, et al. Cancer. 1992 Oct 1;70(7):1988-92. doi: 10.1002/1097-0142(19921001)70:7<1988::aid-cncr2820700730>3.0.co;2-k. Cancer. 1992. PMID: 1381991 Clinical Trial.

3

Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.

Kemeny N, Schneider A, Martin DS, Colofiore J, Sawyer RC, Derby S, Salvia B. Kemeny N, et al. Cancer Res. 1989 Aug 15;49(16):4636-9. Cancer Res. 1989. PMID: 2472883

4

Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.

Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R. Seiter K, et al. Cancer. 1993 Mar 1;71(5):1875-81. doi: 10.1002/1097-0142(19930301)71:5<1875::aid-cncr2820710526>3.0.co;2-9. Cancer. 1993. PMID: 8448752

5

A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.

Schwartz GK, Christman K, Saltz L, Casper E, Quan V, Bertino J, Martin DS, Colofiore J, Kelsen D. Schwartz GK, et al. Cancer. 1996 Nov 1;78(9):1988-95. Cancer. 1996. PMID: 8909321 Clinical Trial.

6

Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance?

Martin DS, Stolfi RL, Colofiore JR. Martin DS, et al. Among authors: colofiore jr. J Natl Cancer Inst. 1988 Jun 1;80(7):496-501. doi: 10.1093/jnci/80.7.496. J Natl Cancer Inst. 1988. PMID: 3259266

7

Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed.

Martin DS, Stolfi RL, Colofiore JR, Nord LD, Sternberg S. Martin DS, et al. Among authors: colofiore jr. Cancer Invest. 1994;12(3):296-307. doi: 10.3109/07357909409023028. Cancer Invest. 1994. PMID: 8187007

8

Potentiation of a three drug chemotherapy regimen by radiation.

Koutcher JA, Alfieri AA, Stolfi RL, Devitt ML, Colofiore JR, Nord LD, Martin DS. Koutcher JA, et al. Among authors: colofiore jr. Cancer Res. 1993 Aug 1;53(15):3518-23. Cancer Res. 1993. PMID: 8339257

9

Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression.

Colofiore JR, Stolfi RL, Nord LD, Martin DS. Colofiore JR, et al. Biochem Pharmacol. 1995 Nov 27;50(11):1943-8. doi: 10.1016/0006-2952(95)02094-2. Biochem Pharmacol. 1995. PMID: 8615876

10

Correlation of retention of tumor methylmercaptopurine riboside-5'-phosphate with effectiveness in CD8F1 murine mammary tumor regression.

Nord LD, Stolfi RL, Colofiore JR, Martin DS. Nord LD, et al. Among authors: colofiore jr. Biochem Pharmacol. 1996 Mar 8;51(5):621-7. doi: 10.1016/s0006-2952(95)02197-3. Biochem Pharmacol. 1996. PMID: 8615898

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters